Full Press Release Details
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis.
BIIB
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
Key Takeaway: Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis